Clinical Trials

380 enrolled

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

380 enrolled

Multiple Myeloma

NCT07227311 2026-05-26

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Recruiting

200 enrolled

Multiple Myeloma

NCT01946477 2026-05-22

POM MM 014

Phase 2 Completed

186 enrolled 17 charts

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT06152575 2026-05-22

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

228 enrolled

Multiple Myeloma, Recurrence

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

261 enrolled

Multiple Myeloma, Recurrence

NCT04181827 2026-05-11

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04973605 2026-05-11

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Phase 2 Active not recruiting

Multiple Myeloma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT04108195 2026-05-08

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

290 enrolled

Multiple Myeloma

NCT04722146 2026-05-08

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT05050097 2026-05-08

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05083169 2026-05-08

MajesTEC-3

587 enrolled 1 FDA

Multiple Myeloma

NCT05438043 2026-05-08

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT06768489 2026-05-08

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Phase 3 Not yet recruiting

Multiple Myeloma

NCT07569757 2026-05-08

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

260 enrolled

Multiple Myeloma

NCT06413498 2026-05-07

iMMagine-3

450 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

Multiple Myeloma

NCT06106945 2026-05-06

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

226 enrolled

Multiple Myeloma

NCT05020236 2026-05-05

MAGNETISMM-5

944 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT02343042 2026-05-04

STOMP

300 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

162 enrolled

Malignant Plasma Cell Neoplasms

NCT07391657 2026-04-30

DURGA-4

508 enrolled

Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

67 enrolled

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04162210 2026-03-31

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT07452198 2026-03-25

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

358 enrolled

Multiple Myeloma

NCT04910568 2026-03-19

CAMMA 1

126 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT05730036 2026-03-06

LINKER-MM3

410 enrolled

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

90 enrolled

Multiple Myeloma, Recurrence

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03287908 2025-10-08

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

174 enrolled

Multiple Myeloma, Neoplasms

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

160 enrolled

Multiple Myeloma, Recurrence

NCT04045795 2025-09-12

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1 Completed

56 enrolled

Multiple Myeloma

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

14 enrolled

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled